DE69924607T2 - Benzimidazol-derivate als ige-modulatoren - Google Patents
Benzimidazol-derivate als ige-modulatoren Download PDFInfo
- Publication number
- DE69924607T2 DE69924607T2 DE69924607T DE69924607T DE69924607T2 DE 69924607 T2 DE69924607 T2 DE 69924607T2 DE 69924607 T DE69924607 T DE 69924607T DE 69924607 T DE69924607 T DE 69924607T DE 69924607 T2 DE69924607 T2 DE 69924607T2
- Authority
- DE
- Germany
- Prior art keywords
- substituted
- group
- cycloalkyl
- cycloaryl
- pharmaceutical composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 229940058303 antinematodal benzimidazole derivative Drugs 0.000 title 1
- 150000001556 benzimidazoles Chemical class 0.000 title 1
- 208000006673 asthma Diseases 0.000 claims abstract description 31
- 238000011282 treatment Methods 0.000 claims abstract description 17
- 239000003112 inhibitor Substances 0.000 claims abstract description 15
- 206010020751 Hypersensitivity Diseases 0.000 claims abstract description 14
- 230000007815 allergy Effects 0.000 claims abstract description 12
- 125000003118 aryl group Chemical group 0.000 claims description 49
- 150000001875 compounds Chemical class 0.000 claims description 33
- 229910052739 hydrogen Inorganic materials 0.000 claims description 21
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 18
- 125000000217 alkyl group Chemical group 0.000 claims description 17
- 125000005073 adamantyl group Chemical group C12(CC3CC(CC(C1)C3)C2)* 0.000 claims description 16
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 16
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims description 16
- 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims description 16
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims description 16
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims description 16
- 239000008194 pharmaceutical composition Substances 0.000 claims description 16
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims description 15
- 239000003814 drug Substances 0.000 claims description 14
- 125000003107 substituted aryl group Chemical group 0.000 claims description 13
- ARUKYTASOALXFG-UHFFFAOYSA-N cycloheptylcycloheptane Chemical group C1CCCCCC1C1CCCCCC1 ARUKYTASOALXFG-UHFFFAOYSA-N 0.000 claims description 8
- NLUNLVTVUDIHFE-UHFFFAOYSA-N cyclooctylcyclooctane Chemical group C1CCCCCCC1C1CCCCCCC1 NLUNLVTVUDIHFE-UHFFFAOYSA-N 0.000 claims description 8
- 230000002757 inflammatory effect Effects 0.000 claims description 8
- 125000005346 substituted cycloalkyl group Chemical group 0.000 claims description 8
- 239000000048 adrenergic agonist Substances 0.000 claims description 7
- 229940126157 adrenergic receptor agonist Drugs 0.000 claims description 7
- 125000001931 aliphatic group Chemical group 0.000 claims description 7
- 150000005350 bicyclononyls Chemical group 0.000 claims description 7
- 208000024891 symptom Diseases 0.000 claims description 6
- 125000003545 alkoxy group Chemical group 0.000 claims description 5
- 125000003282 alkyl amino group Chemical group 0.000 claims description 5
- 239000000739 antihistaminic agent Substances 0.000 claims description 5
- 125000006297 carbonyl amino group Chemical group [H]N([*:2])C([*:1])=O 0.000 claims description 5
- 239000003246 corticosteroid Substances 0.000 claims description 5
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 5
- 229910052736 halogen Inorganic materials 0.000 claims description 5
- 150000002367 halogens Chemical class 0.000 claims description 5
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 5
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 5
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 5
- 238000006467 substitution reaction Methods 0.000 claims description 5
- 239000000812 cholinergic antagonist Substances 0.000 claims description 4
- 239000003199 leukotriene receptor blocking agent Substances 0.000 claims description 4
- 125000000896 monocarboxylic acid group Chemical group 0.000 claims description 4
- 239000002571 phosphodiesterase inhibitor Substances 0.000 claims description 4
- 239000004615 ingredient Substances 0.000 claims description 3
- 229940121948 Muscarinic receptor antagonist Drugs 0.000 claims description 2
- 229940099471 Phosphodiesterase inhibitor Drugs 0.000 claims description 2
- GUGOEEXESWIERI-UHFFFAOYSA-N Terfenadine Chemical compound C1=CC(C(C)(C)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 GUGOEEXESWIERI-UHFFFAOYSA-N 0.000 claims description 2
- 230000001387 anti-histamine Effects 0.000 claims description 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 2
- 238000002360 preparation method Methods 0.000 claims description 2
- 102100030658 Lipase member H Human genes 0.000 claims 1
- 101710102454 Lipase member H Proteins 0.000 claims 1
- 208000030961 allergic reaction Diseases 0.000 claims 1
- 230000004044 response Effects 0.000 abstract description 13
- 201000010099 disease Diseases 0.000 abstract description 10
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 10
- 239000013566 allergen Substances 0.000 abstract description 8
- 150000003384 small molecules Chemical class 0.000 abstract description 8
- 208000026935 allergic disease Diseases 0.000 abstract description 5
- 230000001717 pathogenic effect Effects 0.000 abstract description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 26
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 21
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 21
- 239000011541 reaction mixture Substances 0.000 description 15
- 239000007787 solid Substances 0.000 description 15
- 235000019439 ethyl acetate Nutrition 0.000 description 13
- 239000000047 product Substances 0.000 description 13
- 238000006243 chemical reaction Methods 0.000 description 12
- 229940079593 drug Drugs 0.000 description 12
- 239000000427 antigen Substances 0.000 description 10
- 102000036639 antigens Human genes 0.000 description 10
- 108091007433 antigens Proteins 0.000 description 10
- 238000000034 method Methods 0.000 description 10
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical class CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 10
- 239000000203 mixture Substances 0.000 description 9
- XAFOTXWPFVZQAZ-UHFFFAOYSA-N 2-(4-aminophenyl)-3h-benzimidazol-5-amine Chemical compound C1=CC(N)=CC=C1C1=NC2=CC=C(N)C=C2N1 XAFOTXWPFVZQAZ-UHFFFAOYSA-N 0.000 description 8
- 238000010992 reflux Methods 0.000 description 8
- 238000003756 stirring Methods 0.000 description 8
- 0 *Oc(cc1)ccc1C(Nc(cc1)ccc1C(NC1=CC2)=NC1=CC2NC(C(C1)[C@@]2C=CC1C2)=O)=O Chemical compound *Oc(cc1)ccc1C(Nc(cc1)ccc1C(NC1=CC2)=NC1=CC2NC(C(C1)[C@@]2C=CC1C2)=O)=O 0.000 description 7
- 238000010228 ex vivo assay Methods 0.000 description 7
- 239000000284 extract Substances 0.000 description 7
- 238000005462 in vivo assay Methods 0.000 description 7
- 230000009467 reduction Effects 0.000 description 7
- 239000011734 sodium Substances 0.000 description 7
- KRTDQDCPEZRVGC-UHFFFAOYSA-N 2-nitro-1h-benzimidazole Chemical class C1=CC=C2NC([N+](=O)[O-])=NC2=C1 KRTDQDCPEZRVGC-UHFFFAOYSA-N 0.000 description 6
- OTLNPYWUJOZPPA-UHFFFAOYSA-N 4-nitrobenzoic acid Chemical compound OC(=O)C1=CC=C([N+]([O-])=O)C=C1 OTLNPYWUJOZPPA-UHFFFAOYSA-N 0.000 description 6
- 238000002965 ELISA Methods 0.000 description 6
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 6
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 6
- 238000002347 injection Methods 0.000 description 6
- 239000007924 injection Substances 0.000 description 6
- 238000004949 mass spectrometry Methods 0.000 description 6
- RLOWWWKZYUNIDI-UHFFFAOYSA-N phosphinic chloride Chemical compound ClP=O RLOWWWKZYUNIDI-UHFFFAOYSA-N 0.000 description 6
- 238000000746 purification Methods 0.000 description 6
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 238000004128 high performance liquid chromatography Methods 0.000 description 5
- 229910052708 sodium Inorganic materials 0.000 description 5
- 229910052938 sodium sulfate Inorganic materials 0.000 description 5
- 235000011152 sodium sulphate Nutrition 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- 241000894007 species Species 0.000 description 5
- 230000001629 suppression Effects 0.000 description 5
- 238000003786 synthesis reaction Methods 0.000 description 5
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 4
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 4
- 206010066091 Bronchial Hyperreactivity Diseases 0.000 description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 4
- 241000124008 Mammalia Species 0.000 description 4
- 241000699670 Mus sp. Species 0.000 description 4
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 4
- 239000004480 active ingredient Substances 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 230000036427 bronchial hyperreactivity Effects 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- 230000003828 downregulation Effects 0.000 description 4
- 238000000338 in vitro Methods 0.000 description 4
- 238000002156 mixing Methods 0.000 description 4
- 229920000728 polyester Polymers 0.000 description 4
- 238000004007 reversed phase HPLC Methods 0.000 description 4
- 239000000741 silica gel Substances 0.000 description 4
- 229910002027 silica gel Inorganic materials 0.000 description 4
- 238000011269 treatment regimen Methods 0.000 description 4
- XWTYSIMOBUGWOL-UHFFFAOYSA-N (+-)-Terbutaline Chemical compound CC(C)(C)NCC(O)C1=CC(O)=CC(O)=C1 XWTYSIMOBUGWOL-UHFFFAOYSA-N 0.000 description 3
- NGNBDVOYPDDBFK-UHFFFAOYSA-N 2-[2,4-di(pentan-2-yl)phenoxy]acetyl chloride Chemical compound CCCC(C)C1=CC=C(OCC(Cl)=O)C(C(C)CCC)=C1 NGNBDVOYPDDBFK-UHFFFAOYSA-N 0.000 description 3
- UUWFEGGBFPDNEU-UHFFFAOYSA-N 4-(4-methyl-1h-benzimidazol-2-yl)aniline Chemical compound N=1C=2C(C)=CC=CC=2NC=1C1=CC=C(N)C=C1 UUWFEGGBFPDNEU-UHFFFAOYSA-N 0.000 description 3
- OBZWACQMTOBFSX-UHFFFAOYSA-N 4-(5,6-dichloro-1h-benzimidazol-2-yl)aniline Chemical compound C1=CC(N)=CC=C1C1=NC2=CC(Cl)=C(Cl)C=C2N1 OBZWACQMTOBFSX-UHFFFAOYSA-N 0.000 description 3
- VFCIVOLORKWIBB-UHFFFAOYSA-N 4-(5,6-dimethyl-1h-benzimidazol-2-yl)aniline Chemical compound N1C=2C=C(C)C(C)=CC=2N=C1C1=CC=C(N)C=C1 VFCIVOLORKWIBB-UHFFFAOYSA-N 0.000 description 3
- HKZKSLMDWRZRAM-UHFFFAOYSA-N 4-(6-methoxy-1h-benzimidazol-2-yl)aniline Chemical compound N1C2=CC(OC)=CC=C2N=C1C1=CC=C(N)C=C1 HKZKSLMDWRZRAM-UHFFFAOYSA-N 0.000 description 3
- BQAHOIQJVNOZKN-UHFFFAOYSA-N 4-(6-methyl-1h-benzimidazol-2-yl)aniline Chemical compound N1C2=CC(C)=CC=C2N=C1C1=CC=C(N)C=C1 BQAHOIQJVNOZKN-UHFFFAOYSA-N 0.000 description 3
- XJIPBORERCFIIP-UHFFFAOYSA-N 6-nitro-2-(4-nitrophenyl)-1h-benzimidazole Chemical compound C1=CC([N+](=O)[O-])=CC=C1C1=NC2=CC=C([N+]([O-])=O)C=C2N1 XJIPBORERCFIIP-UHFFFAOYSA-N 0.000 description 3
- MBUVEWMHONZEQD-UHFFFAOYSA-N Azeptin Chemical compound C1CN(C)CCCC1N1C(=O)C2=CC=CC=C2C(CC=2C=CC(Cl)=CC=2)=N1 MBUVEWMHONZEQD-UHFFFAOYSA-N 0.000 description 3
- 206010006482 Bronchospasm Diseases 0.000 description 3
- 241000283707 Capra Species 0.000 description 3
- ZCVMWBYGMWKGHF-UHFFFAOYSA-N Ketotifene Chemical compound C1CN(C)CCC1=C1C2=CC=CC=C2CC(=O)C2=C1C=CS2 ZCVMWBYGMWKGHF-UHFFFAOYSA-N 0.000 description 3
- GIIZNNXWQWCKIB-UHFFFAOYSA-N Serevent Chemical compound C1=C(O)C(CO)=CC(C(O)CNCCCCCCOCCCCC=2C=CC=CC=2)=C1 GIIZNNXWQWCKIB-UHFFFAOYSA-N 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- NDAUXUAQIAJITI-UHFFFAOYSA-N albuterol Chemical compound CC(C)(C)NCC(O)C1=CC=C(O)C(CO)=C1 NDAUXUAQIAJITI-UHFFFAOYSA-N 0.000 description 3
- DIZPMCHEQGEION-UHFFFAOYSA-H aluminium sulfate (anhydrous) Chemical compound [Al+3].[Al+3].[O-]S([O-])(=O)=O.[O-]S([O-])(=O)=O.[O-]S([O-])(=O)=O DIZPMCHEQGEION-UHFFFAOYSA-H 0.000 description 3
- 230000003110 anti-inflammatory effect Effects 0.000 description 3
- 229940125715 antihistaminic agent Drugs 0.000 description 3
- 229960004574 azelastine Drugs 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- 229940098773 bovine serum albumin Drugs 0.000 description 3
- 230000007885 bronchoconstriction Effects 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 239000012091 fetal bovine serum Substances 0.000 description 3
- 229960002848 formoterol Drugs 0.000 description 3
- BPZSYCZIITTYBL-UHFFFAOYSA-N formoterol Chemical compound C1=CC(OC)=CC=C1CC(C)NCC(O)C1=CC=C(O)C(NC=O)=C1 BPZSYCZIITTYBL-UHFFFAOYSA-N 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 229960004958 ketotifen Drugs 0.000 description 3
- 230000001404 mediated effect Effects 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 230000000737 periodic effect Effects 0.000 description 3
- 239000002244 precipitate Substances 0.000 description 3
- 230000037452 priming Effects 0.000 description 3
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 3
- 210000002345 respiratory system Anatomy 0.000 description 3
- 229960002052 salbutamol Drugs 0.000 description 3
- 229960004017 salmeterol Drugs 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- 229960000195 terbutaline Drugs 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- XSZYBMMYQCYIPC-UHFFFAOYSA-N 4,5-dimethyl-1,2-phenylenediamine Chemical compound CC1=CC(N)=C(N)C=C1C XSZYBMMYQCYIPC-UHFFFAOYSA-N 0.000 description 2
- ALYNCZNDIQEVRV-UHFFFAOYSA-N 4-aminobenzoic acid Chemical compound NC1=CC=C(C(O)=O)C=C1 ALYNCZNDIQEVRV-UHFFFAOYSA-N 0.000 description 2
- 229960000549 4-dimethylaminophenol Drugs 0.000 description 2
- OEHCBEYCJFRMCE-UHFFFAOYSA-N 4-methyl-2-(4-nitrophenyl)-1h-benzimidazole Chemical compound N=1C=2C(C)=CC=CC=2NC=1C1=CC=C([N+]([O-])=O)C=C1 OEHCBEYCJFRMCE-UHFFFAOYSA-N 0.000 description 2
- RAUWPNXIALNKQM-UHFFFAOYSA-N 4-nitro-1,2-phenylenediamine Chemical compound NC1=CC=C([N+]([O-])=O)C=C1N RAUWPNXIALNKQM-UHFFFAOYSA-N 0.000 description 2
- SAIKSEKQKPKCOU-UHFFFAOYSA-N 5,6-dichloro-2-(4-nitrophenyl)-1h-benzimidazole Chemical compound C1=CC([N+](=O)[O-])=CC=C1C1=NC2=CC(Cl)=C(Cl)C=C2N1 SAIKSEKQKPKCOU-UHFFFAOYSA-N 0.000 description 2
- YXQOJLWDLRRADB-UHFFFAOYSA-N 5,6-dimethyl-2-(4-nitrophenyl)-1h-benzimidazole Chemical compound N1C=2C=C(C)C(C)=CC=2N=C1C1=CC=C([N+]([O-])=O)C=C1 YXQOJLWDLRRADB-UHFFFAOYSA-N 0.000 description 2
- KAPGWRWXNVNLPT-UHFFFAOYSA-N 6-methoxy-2-(4-nitrophenyl)-1h-benzimidazole Chemical compound N1C2=CC(OC)=CC=C2N=C1C1=CC=C([N+]([O-])=O)C=C1 KAPGWRWXNVNLPT-UHFFFAOYSA-N 0.000 description 2
- PFIPEWJKRTWVRM-UHFFFAOYSA-N 6-methyl-2-(4-nitrophenyl)-1h-benzimidazole Chemical compound N1C2=CC(C)=CC=C2N=C1C1=CC=C([N+]([O-])=O)C=C1 PFIPEWJKRTWVRM-UHFFFAOYSA-N 0.000 description 2
- 238000011731 BALB/cByJ (JAX™ mouse strain) Methods 0.000 description 2
- 238000012286 ELISA Assay Methods 0.000 description 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 206010070834 Sensitisation Diseases 0.000 description 2
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 208000027418 Wounds and injury Diseases 0.000 description 2
- 239000008186 active pharmaceutical agent Substances 0.000 description 2
- 239000013543 active substance Substances 0.000 description 2
- 239000000556 agonist Substances 0.000 description 2
- 201000009961 allergic asthma Diseases 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 229940121363 anti-inflammatory agent Drugs 0.000 description 2
- 239000002260 anti-inflammatory agent Substances 0.000 description 2
- 229940065524 anticholinergics inhalants for obstructive airway diseases Drugs 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 239000012298 atmosphere Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 229940124630 bronchodilator Drugs 0.000 description 2
- 229940082638 cardiac stimulant phosphodiesterase inhibitors Drugs 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 150000001805 chlorine compounds Chemical class 0.000 description 2
- 229960001334 corticosteroids Drugs 0.000 description 2
- 229960000265 cromoglicic acid Drugs 0.000 description 2
- IMZMKUWMOSJXDT-UHFFFAOYSA-N cromoglycic acid Chemical compound O1C(C(O)=O)=CC(=O)C2=C1C=CC=C2OCC(O)COC1=CC=CC2=C1C(=O)C=C(C(O)=O)O2 IMZMKUWMOSJXDT-UHFFFAOYSA-N 0.000 description 2
- 239000012228 culture supernatant Substances 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 231100000673 dose–response relationship Toxicity 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 229960001340 histamine Drugs 0.000 description 2
- 210000003630 histaminocyte Anatomy 0.000 description 2
- 239000001257 hydrogen Substances 0.000 description 2
- 230000001976 improved effect Effects 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 230000028709 inflammatory response Effects 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- 150000002500 ions Chemical class 0.000 description 2
- 229940065725 leukotriene receptor antagonists for obstructive airway diseases Drugs 0.000 description 2
- 150000002617 leukotrienes Chemical class 0.000 description 2
- 229960003088 loratadine Drugs 0.000 description 2
- JCCNYMKQOSZNPW-UHFFFAOYSA-N loratadine Chemical compound C1CN(C(=O)OCC)CCC1=C1C2=NC=CC=C2CCC2=CC(Cl)=CC=C21 JCCNYMKQOSZNPW-UHFFFAOYSA-N 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 238000001819 mass spectrum Methods 0.000 description 2
- 229960004398 nedocromil Drugs 0.000 description 2
- RQTOOFIXOKYGAN-UHFFFAOYSA-N nedocromil Chemical compound CCN1C(C(O)=O)=CC(=O)C2=C1C(CCC)=C1OC(C(O)=O)=CC(=O)C1=C2 RQTOOFIXOKYGAN-UHFFFAOYSA-N 0.000 description 2
- 239000012044 organic layer Substances 0.000 description 2
- 239000002953 phosphate buffered saline Substances 0.000 description 2
- XHXFXVLFKHQFAL-UHFFFAOYSA-N phosphoryl trichloride Chemical compound ClP(Cl)(Cl)=O XHXFXVLFKHQFAL-UHFFFAOYSA-N 0.000 description 2
- 230000008313 sensitization Effects 0.000 description 2
- 235000017557 sodium bicarbonate Nutrition 0.000 description 2
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 210000004989 spleen cell Anatomy 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- ZFXYFBGIUFBOJW-UHFFFAOYSA-N theophylline Chemical compound O=C1N(C)C(=O)N(C)C2=C1NC=N2 ZFXYFBGIUFBOJW-UHFFFAOYSA-N 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 238000004809 thin layer chromatography Methods 0.000 description 2
- 230000001960 triggered effect Effects 0.000 description 2
- 239000003643 water by type Substances 0.000 description 2
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 2
- HYZJCKYKOHLVJF-UHFFFAOYSA-N 1H-benzimidazole Chemical compound C1=CC=C2NC=NC2=C1 HYZJCKYKOHLVJF-UHFFFAOYSA-N 0.000 description 1
- HXRKRXJSDNRWDY-UHFFFAOYSA-N 2,4-dinitro-1h-benzimidazole Chemical compound C1=CC([N+]([O-])=O)=C2NC([N+](=O)[O-])=NC2=C1 HXRKRXJSDNRWDY-UHFFFAOYSA-N 0.000 description 1
- AXNUJYHFQHQZBE-UHFFFAOYSA-N 3-methylbenzene-1,2-diamine Chemical compound CC1=CC=CC(N)=C1N AXNUJYHFQHQZBE-UHFFFAOYSA-N 0.000 description 1
- IWFHBRFJOHTIPU-UHFFFAOYSA-N 4,5-dichlorobenzene-1,2-diamine Chemical compound NC1=CC(Cl)=C(Cl)C=C1N IWFHBRFJOHTIPU-UHFFFAOYSA-N 0.000 description 1
- AGAHETWGCFCMDK-UHFFFAOYSA-N 4-methoxybenzene-1,2-diamine Chemical compound COC1=CC=C(N)C(N)=C1 AGAHETWGCFCMDK-UHFFFAOYSA-N 0.000 description 1
- DGRGLKZMKWPMOH-UHFFFAOYSA-N 4-methylbenzene-1,2-diamine Chemical compound CC1=CC=C(N)C(N)=C1 DGRGLKZMKWPMOH-UHFFFAOYSA-N 0.000 description 1
- LRFVTYWOQMYALW-UHFFFAOYSA-N 9H-xanthine Chemical class O=C1NC(=O)NC2=C1NC=N2 LRFVTYWOQMYALW-UHFFFAOYSA-N 0.000 description 1
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 1
- VOVIALXJUBGFJZ-KWVAZRHASA-N Budesonide Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1C[C@H]3OC(CCC)O[C@@]3(C(=O)CO)[C@@]1(C)C[C@@H]2O VOVIALXJUBGFJZ-KWVAZRHASA-N 0.000 description 1
- OECQMMXFPLOOES-UHFFFAOYSA-N COc(cc1)ccc1C(Nc(cc1)ccc1-c1nc2cc(NC(c3ccccc3)=O)ccc2[nH]1)=O Chemical compound COc(cc1)ccc1C(Nc(cc1)ccc1-c1nc2cc(NC(c3ccccc3)=O)ccc2[nH]1)=O OECQMMXFPLOOES-UHFFFAOYSA-N 0.000 description 1
- 206010008469 Chest discomfort Diseases 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 1
- CTOJUVGMIWAABB-UHFFFAOYSA-N O=C(C1(C2)C(C3)CC2CC3C1)Nc1ccc(-c2nc(cc(cc3)NC(c4ncccc4)=O)c3[nH]2)cc1 Chemical compound O=C(C1(C2)C(C3)CC2CC3C1)Nc1ccc(-c2nc(cc(cc3)NC(c4ncccc4)=O)c3[nH]2)cc1 CTOJUVGMIWAABB-UHFFFAOYSA-N 0.000 description 1
- XXHGMGHPFYHOEO-UHFFFAOYSA-N O=C(C1C(C2)C=CC2C1)Nc(cc1)cc2c1[nH]c(-c(cc1)ccc1NC(c1c[s]cc1)=O)n2 Chemical compound O=C(C1C(C2)C=CC2C1)Nc(cc1)cc2c1[nH]c(-c(cc1)ccc1NC(c1c[s]cc1)=O)n2 XXHGMGHPFYHOEO-UHFFFAOYSA-N 0.000 description 1
- DAXZVVAQIQWXBK-UHFFFAOYSA-N O=C(C1C(CC2)CC2C1)Nc(cc1)ccc1-c1nc2cc(NC(c3ccccc3)=O)ccc2[nH]1 Chemical compound O=C(C1C(CC2)CC2C1)Nc(cc1)ccc1-c1nc2cc(NC(c3ccccc3)=O)ccc2[nH]1 DAXZVVAQIQWXBK-UHFFFAOYSA-N 0.000 description 1
- OMXGRPKJPUIAHO-UHFFFAOYSA-N O=C(C1CCCC1)Nc(cc1)ccc1-c1nc(cc(cc2)NC(c3ccccc3)=O)c2[nH]1 Chemical compound O=C(C1CCCC1)Nc(cc1)ccc1-c1nc(cc(cc2)NC(c3ccccc3)=O)c2[nH]1 OMXGRPKJPUIAHO-UHFFFAOYSA-N 0.000 description 1
- YSLZDYOJTLARKX-UHFFFAOYSA-N O=C(C1CCCCCC1)Nc(cc1)ccc1-c1nc2cc(NC(c3ccccc3)=O)ccc2[nH]1 Chemical compound O=C(C1CCCCCC1)Nc(cc1)ccc1-c1nc2cc(NC(c3ccccc3)=O)ccc2[nH]1 YSLZDYOJTLARKX-UHFFFAOYSA-N 0.000 description 1
- IPJKBVAENADRRK-GTPZEUEISA-N O=C(C1[C@@H](CC2)CC2C1)Nc1ccc2[nH]c(-c(cc3)ccc3NC(c3ccccc3)=O)nc2c1 Chemical compound O=C(C1[C@@H](CC2)CC2C1)Nc1ccc2[nH]c(-c(cc3)ccc3NC(c3ccccc3)=O)nc2c1 IPJKBVAENADRRK-GTPZEUEISA-N 0.000 description 1
- OQTIJLGTNVJUJI-JGCRXCKMSA-N O=C(C1[C@H](C2)C=CC2C1)N[o]1ccc2[nH]c(-c(cc3)ccc3NC(c3cnccc3)=O)nc2c1 Chemical compound O=C(C1[C@H](C2)C=CC2C1)N[o]1ccc2[nH]c(-c(cc3)ccc3NC(c3cnccc3)=O)nc2c1 OQTIJLGTNVJUJI-JGCRXCKMSA-N 0.000 description 1
- YPEDTLAWDVNZLQ-LAGYLCCXSA-N O=C([C@@H]1C(C2)C=CC2C1)Nc(cc1)cc2c1[nH]c(-c(cc1)ccc1NC(c1ccc[s]1)=O)n2 Chemical compound O=C([C@@H]1C(C2)C=CC2C1)Nc(cc1)cc2c1[nH]c(-c(cc1)ccc1NC(c1ccc[s]1)=O)n2 YPEDTLAWDVNZLQ-LAGYLCCXSA-N 0.000 description 1
- VQSDVRLHURFHRD-UHFFFAOYSA-N O=C(c1ccccc1)Nc(cc1)cc2c1[nH]c(-c(cc1)ccc1NC(c1cc(Cl)cc(Cl)c1)=O)n2 Chemical compound O=C(c1ccccc1)Nc(cc1)cc2c1[nH]c(-c(cc1)ccc1NC(c1cc(Cl)cc(Cl)c1)=O)n2 VQSDVRLHURFHRD-UHFFFAOYSA-N 0.000 description 1
- WOURIGHVPROFMH-UHFFFAOYSA-N O=C(c1ccccc1)Nc1ccc2[nH]c(-c(cc3)ccc3NC(c(cc3)ccc3Cl)=O)nc2c1 Chemical compound O=C(c1ccccc1)Nc1ccc2[nH]c(-c(cc3)ccc3NC(c(cc3)ccc3Cl)=O)nc2c1 WOURIGHVPROFMH-UHFFFAOYSA-N 0.000 description 1
- BVWMTINAYQUJIV-UHFFFAOYSA-N O=C(c1ccccc1)Nc1ccc2[nH]c(-c(cc3)ccc3NC(c3cnccc3)=O)nc2c1 Chemical compound O=C(c1ccccc1)Nc1ccc2[nH]c(-c(cc3)ccc3NC(c3cnccc3)=O)nc2c1 BVWMTINAYQUJIV-UHFFFAOYSA-N 0.000 description 1
- NYZRRDNDTGXUTA-UHFFFAOYSA-N O=C(c1cnccc1)Nc(cc1)ccc1-c1nc2cc(NC(c3cccnc3)=O)ccc2[nH]1 Chemical compound O=C(c1cnccc1)Nc(cc1)ccc1-c1nc2cc(NC(c3cccnc3)=O)ccc2[nH]1 NYZRRDNDTGXUTA-UHFFFAOYSA-N 0.000 description 1
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium on carbon Substances [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- 206010038687 Respiratory distress Diseases 0.000 description 1
- 206010039085 Rhinitis allergic Diseases 0.000 description 1
- 206010040844 Skin exfoliation Diseases 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 229910021626 Tin(II) chloride Inorganic materials 0.000 description 1
- YEEZWCHGZNKEEK-UHFFFAOYSA-N Zafirlukast Chemical compound COC1=CC(C(=O)NS(=O)(=O)C=2C(=CC=CC=2)C)=CC=C1CC(C1=C2)=CN(C)C1=CC=C2NC(=O)OC1CCCC1 YEEZWCHGZNKEEK-UHFFFAOYSA-N 0.000 description 1
- 208000024716 acute asthma Diseases 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 208000037883 airway inflammation Diseases 0.000 description 1
- 201000010105 allergic rhinitis Diseases 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- 229960004050 aminobenzoic acid Drugs 0.000 description 1
- 239000000908 ammonium hydroxide Substances 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 230000003435 bronchoconstrictive effect Effects 0.000 description 1
- 230000007883 bronchodilation Effects 0.000 description 1
- 239000000168 bronchodilator agent Substances 0.000 description 1
- 229960004436 budesonide Drugs 0.000 description 1
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- CIPMQPTWGWCBLF-UHFFFAOYSA-N chembl382387 Chemical compound C=1C(CC(=O)O)=CC(C=2NC3=CC=CC=C3N=2)=C(O)C=1C1=CC=CC([N+]([O-])=O)=C1 CIPMQPTWGWCBLF-UHFFFAOYSA-N 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 238000002648 combination therapy Methods 0.000 description 1
- 230000009260 cross reactivity Effects 0.000 description 1
- 239000012043 crude product Substances 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- 238000011461 current therapy Methods 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 230000035618 desquamation Effects 0.000 description 1
- 150000001470 diamides Chemical class 0.000 description 1
- 239000010432 diamond Substances 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 238000000132 electrospray ionisation Methods 0.000 description 1
- 238000002330 electrospray ionisation mass spectrometry Methods 0.000 description 1
- 210000003979 eosinophil Anatomy 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 238000003818 flash chromatography Methods 0.000 description 1
- 230000000004 hemodynamic effect Effects 0.000 description 1
- 150000003840 hydrochlorides Chemical class 0.000 description 1
- 239000005457 ice water Substances 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 210000004969 inflammatory cell Anatomy 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 239000002085 irritant Substances 0.000 description 1
- 231100000021 irritant Toxicity 0.000 description 1
- 239000010410 layer Substances 0.000 description 1
- 238000012153 long-term therapy Methods 0.000 description 1
- 238000011866 long-term treatment Methods 0.000 description 1
- 238000002483 medication Methods 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 210000003097 mucus Anatomy 0.000 description 1
- 150000002790 naphthalenes Chemical class 0.000 description 1
- 230000003472 neutralizing effect Effects 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 238000002638 palliative care Methods 0.000 description 1
- 230000035778 pathophysiological process Effects 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 238000001050 pharmacotherapy Methods 0.000 description 1
- 239000000902 placebo Substances 0.000 description 1
- 229940068196 placebo Drugs 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 230000001235 sensitizing effect Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 235000011150 stannous chloride Nutrition 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 229940065721 systemic for obstructive airway disease xanthines Drugs 0.000 description 1
- 229960000278 theophylline Drugs 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- AXZWODMDQAVCJE-UHFFFAOYSA-L tin(II) chloride (anhydrous) Chemical compound [Cl-].[Cl-].[Sn+2] AXZWODMDQAVCJE-UHFFFAOYSA-L 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Pulmonology (AREA)
- Immunology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Amplifiers (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Indole Compounds (AREA)
- Heterocyclic Compounds That Contain Two Or More Ring Oxygen Atoms (AREA)
- Hydrogenated Pyridines (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US8649498P | 1998-05-22 | 1998-05-22 | |
| US86494P | 1998-05-22 | ||
| PCT/US1999/011322 WO1999061019A1 (en) | 1998-05-22 | 1999-05-21 | BENZIMIDAZOLE DERIVATIVES AS MODULATORS OF IgE |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| DE69924607D1 DE69924607D1 (de) | 2005-05-12 |
| DE69924607T2 true DE69924607T2 (de) | 2006-02-02 |
Family
ID=22198947
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE69924607T Expired - Fee Related DE69924607T2 (de) | 1998-05-22 | 1999-05-21 | Benzimidazol-derivate als ige-modulatoren |
Country Status (22)
| Country | Link |
|---|---|
| US (2) | US6271390B1 (https=) |
| EP (3) | EP1079830A1 (https=) |
| JP (3) | JP2002516277A (https=) |
| KR (1) | KR100591652B1 (https=) |
| CN (4) | CN1311675A (https=) |
| AT (1) | ATE292465T1 (https=) |
| AU (3) | AU754562B2 (https=) |
| BR (3) | BR9910642A (https=) |
| CA (3) | CA2332985A1 (https=) |
| CZ (2) | CZ20004351A3 (https=) |
| DE (1) | DE69924607T2 (https=) |
| ES (1) | ES2241285T3 (https=) |
| HU (3) | HUP0102128A3 (https=) |
| IL (3) | IL139828A0 (https=) |
| MX (3) | MXPA00011422A (https=) |
| NO (3) | NO20005889L (https=) |
| NZ (2) | NZ508416A (https=) |
| PL (3) | PL345560A1 (https=) |
| RU (2) | RU2236221C2 (https=) |
| UA (2) | UA67775C2 (https=) |
| WO (3) | WO1999061020A1 (https=) |
| ZA (3) | ZA200007754B (https=) |
Families Citing this family (57)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6919366B2 (en) | 1998-05-22 | 2005-07-19 | Avanir Pharmaceuticals | Benzimidazole derivatives as modulators of IgE |
| US6911462B2 (en) * | 1998-05-22 | 2005-06-28 | Avanir Pharmaceuticals | Benzimidazole compounds for regulating IgE |
| BR9910642A (pt) * | 1998-05-22 | 2001-10-09 | Avanir Pharmaceuticals | Análogos de benzimidazol como reguladores descendentes de ige |
| BR9913562A (pt) | 1998-09-11 | 2001-05-22 | Ajinomoto Kk | Derivados de benzeno, inibidor de ativação de ap-1 e nf-capa b, inibidor de produção de citoquina inflamatória, inibidor de produção de metaloprotease matricial ou inibidor de aparecimento de fator de adesão de célula inflamatório, e, agente antiinflamatório, anti-reumático, imunossupressor, inibidor de metástase cancerosa, remédio para arterioesclerose e agente antiviral |
| US6270746B1 (en) * | 1999-02-17 | 2001-08-07 | David H. Katz | Assay for the identification of IgE antibody suppressors |
| TW502019B (en) * | 1999-03-26 | 2002-09-11 | Cocensys Inc | Aryl substituted pyrazoles, imidazoles, oxazoles, thiazoles and pyrroles, and the use thereof |
| BR0012046A (pt) | 1999-07-01 | 2002-05-14 | Ajinomoto Kk | Composto heterocìclico, composição farmacêutica, inibidor de ativação de ap-1 ou um inibidor da ativação de nf-kappab, inibidor da produção de citocina inflamatória, e, inibidor da produção de metaloprotease de matriz ou inibidor da expressão do fator de adesão de célula inflamatória |
| WO2001016091A1 (en) | 1999-09-01 | 2001-03-08 | Ajinomoto Co.,Inc. | Biscyclopropanecarboxylic acid amide compounds and medicinal use thereof |
| US6759425B2 (en) | 1999-10-21 | 2004-07-06 | Avanir Pharmaceuticals | Benzimidazole compounds for modulating IgE and inhibiting cellular proliferation |
| US6448281B1 (en) | 2000-07-06 | 2002-09-10 | Boehringer Ingelheim (Canada) Ltd. | Viral polymerase inhibitors |
| US20070208087A1 (en) | 2001-11-02 | 2007-09-06 | Sanders Virginia J | Compounds, compositions and methods for the treatment of inflammatory diseases |
| CZ20032691A3 (en) * | 2001-03-12 | 2004-04-14 | Avanir Pharmaceuticals | Benzimidazole compounds for modulating ige and inhibiting cellular proliferation |
| EP2335700A1 (en) | 2001-07-25 | 2011-06-22 | Boehringer Ingelheim (Canada) Ltd. | Hepatitis C virus polymerase inhibitors with a heterobicylic structure |
| BR0211513A (pt) * | 2001-07-27 | 2005-08-30 | Curis Inc | Mediadores de caminhos sinalizantes de hedgehog, composições e usos relacionados ao mesmo |
| ATE369854T1 (de) | 2001-10-19 | 2007-09-15 | Ortho Mcneil Pharm Inc | 2-phenyl benzimidazole und imidazo-[4,5]-pyridine als cds1/chk2-inhibitoren und adjuvantien in der chemotherapie oder strahlungstherapie zur behandlung von krebs |
| US20080081788A1 (en) * | 2002-01-14 | 2008-04-03 | Lipps Binie V | Diagnosis and treatment for immunoglobulin E (IgE) implicated disorders |
| US20030157555A1 (en) * | 2002-01-14 | 2003-08-21 | Lipps Binie V. | Diagnosis and treatment for immunoglobulin E ( IgE) implicated disorders |
| TW200304820A (en) * | 2002-03-25 | 2003-10-16 | Avanir Pharmaceuticals | Use of benzimidazole analogs in the treatment of cell proliferation |
| WO2003101927A1 (en) | 2002-05-31 | 2003-12-11 | Proteotech, Inc. | Compounds, compositions and methods for the treatment of amyloid diseases and synucleinopathies such as alzheimer's disease, type 2 diabetes, and parkinson's disease |
| EP1388535A1 (en) | 2002-08-07 | 2004-02-11 | Aventis Pharma Deutschland GmbH | Acylated arylcycloalkylamines and their use as pharmaceuticals |
| DK1534335T4 (en) | 2002-08-14 | 2015-10-05 | Macrogenics Inc | FCGAMMARIIB-SPECIFIC ANTIBODIES AND PROCEDURES FOR USE THEREOF |
| WO2004024655A2 (en) | 2002-09-12 | 2004-03-25 | Avanir Pharmaceuticals | Phenyl-indole compounds for modulating ige and inhibiting cellular proliferation |
| TWI276631B (en) * | 2002-09-12 | 2007-03-21 | Avanir Pharmaceuticals | Phenyl-aza-benzimidazole compounds for modulating IgE and inhibiting cellular proliferation |
| US20050239844A1 (en) * | 2002-11-02 | 2005-10-27 | Kyung-Lim Lee | Composition fo preventing secretion of immunoglobulin e-dependent histamine releasing factor |
| GB2397301A (en) * | 2003-01-14 | 2004-07-21 | Novo Pharmaceuticals Ltd De | Substituted 1,3,5-triazine derivatives |
| US7132440B2 (en) | 2003-04-17 | 2006-11-07 | Janssen Pharmaceutica, N.V. | Substituted benzimidazoles and imidazo-[4,5]-pyridines |
| EP1651198A2 (en) * | 2003-08-08 | 2006-05-03 | Avanir Pharmaceuticals | Selective pharmacologic inhibition of protein trafficking and related methods of treating human diseases |
| CN102911161A (zh) | 2004-02-20 | 2013-02-06 | 贝林格尔.英格海姆国际有限公司 | 病毒聚合酶抑制剂 |
| ATE453617T1 (de) * | 2004-05-12 | 2010-01-15 | Proteotech Inc | Substituierte n-arylbenzamide und verwandte verbindungen zur behandlung von amyloidkrankheiten und synukleinopathien |
| ES2362102T3 (es) | 2004-06-30 | 2011-06-28 | Janssen Pharmaceutica Nv | Eteres de bencimidazol e imidazopiridina sustituidos con arilo como agentes anticáncer. |
| WO2006040645A1 (en) * | 2004-10-11 | 2006-04-20 | Ranbaxy Laboratories Limited | N-(3,5-dichloropyridin-4-yl)-2,4,5-alkoxy and 2,3,4-alkoxy benzamide derivatives as pde-iv (phophodiesterase type-iv) inhibitors for the treatment of inflammatory diseases such as asthma |
| JP5301999B2 (ja) † | 2005-10-31 | 2013-09-25 | メルク・シャープ・アンド・ドーム・コーポレーション | Ｃｅｔｐ阻害薬 |
| EP1790345A1 (en) * | 2005-11-02 | 2007-05-30 | Esbatech AG | Triazin beta-secretase inhibitors |
| US7671221B2 (en) * | 2005-12-28 | 2010-03-02 | Vertex Pharmaceuticals Incorporated | Modulators of ATP-Binding Cassette transporters |
| AU2006336504C9 (en) * | 2005-12-28 | 2015-05-14 | Vertex Pharmaceuticals Incorporated | 1-(benzo [D] [1,3] dioxol-5-yl) -N- (phenyl) cyclopropane- carboxamide derivatives and related compounds as modulators of ATP-Binding Cassette transporters for the treatment of Cystic Fibrosis |
| ES2599319T3 (es) | 2006-06-26 | 2017-02-01 | Macrogenics, Inc. | Anticuerpos específicos de Fc RIIB y métodos de uso de éstos |
| WO2010045633A2 (en) * | 2008-10-17 | 2010-04-22 | National Jewish Health | Measurement and analysis of leukotrienes |
| US8546405B2 (en) | 2008-12-23 | 2013-10-01 | Abbott Laboratories | Anti-viral compounds |
| SG172352A1 (en) | 2008-12-23 | 2011-07-28 | Abbott Lab | Anti-viral compounds |
| US9278922B2 (en) | 2009-04-15 | 2016-03-08 | Abbvie Inc. | Anti-viral compounds |
| US8937150B2 (en) | 2009-06-11 | 2015-01-20 | Abbvie Inc. | Anti-viral compounds |
| US9394279B2 (en) | 2009-06-11 | 2016-07-19 | Abbvie Inc. | Anti-viral compounds |
| US8716454B2 (en) | 2009-06-11 | 2014-05-06 | Abbvie Inc. | Solid compositions |
| EA020031B1 (ru) | 2009-06-11 | 2014-08-29 | Эббви Бахамаз Лтд. | Противовирусные соединения |
| US8420655B2 (en) | 2009-12-04 | 2013-04-16 | Boehringer Ingelheim International Gmbh | Benzimidazole inhibitors of leukotriene production |
| NZ605440A (en) | 2010-06-10 | 2014-05-30 | Abbvie Bahamas Ltd | Solid compositions comprising an hcv inhibitor |
| US9321735B2 (en) | 2010-07-20 | 2016-04-26 | Vestaron Corporation | Insecticidal triazines and pyrimidines |
| JP5928958B2 (ja) | 2010-10-29 | 2016-06-01 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | ロイコトリエン生成のベンゾイミダゾールインヒビター |
| WO2012061169A1 (en) | 2010-11-01 | 2012-05-10 | Boehringer Ingelheim International Gmbh | Benzimidazole inhibitors of leukotriene production |
| US10201584B1 (en) | 2011-05-17 | 2019-02-12 | Abbvie Inc. | Compositions and methods for treating HCV |
| US9034832B2 (en) | 2011-12-29 | 2015-05-19 | Abbvie Inc. | Solid compositions |
| US11484534B2 (en) | 2013-03-14 | 2022-11-01 | Abbvie Inc. | Methods for treating HCV |
| WO2015103490A1 (en) | 2014-01-03 | 2015-07-09 | Abbvie, Inc. | Solid antiviral dosage forms |
| US11548867B2 (en) | 2017-07-19 | 2023-01-10 | Idea Ya Biosciences, Inc. | Amido compounds as AhR modulators |
| NZ773110A (en) * | 2018-09-18 | 2024-11-29 | Terns Inc | Compounds for treating certain leukemias |
| CN110054558B (zh) * | 2019-05-16 | 2022-03-25 | 海门瑞一医药科技有限公司 | 一种1-三氟甲基环丙烷-1-甲酸的制备方法 |
| CN112441983B (zh) * | 2019-08-29 | 2023-09-15 | 山东福长药业有限公司 | 一种基于苯并咪唑取代的硝基苯的化合物及其制备方法 |
Family Cites Families (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3017610A (en) * | 1957-03-15 | 1962-01-16 | Curtiss Wright Corp | Electronic data file processor |
| US4939133A (en) | 1985-10-01 | 1990-07-03 | Warner-Lambert Company | N-substituted-2-hydroxy-α-oxo-benzeneacetamides and pharmaceutical compositions having activity as modulators of the arachidonic acid cascade |
| LU86258A1 (fr) | 1986-01-21 | 1987-09-03 | Rech Dermatologiques C I R D S | Composes benzamido aromatique,leur procede de preparation et leur utilisation en medecine humaine ou veterinaire et en cosmetique |
| US4744026A (en) * | 1986-04-11 | 1988-05-10 | American Telephone And Telegraph Company, At&T Bell Laboratories | Methods and apparatus for efficient resource allocation |
| IT1232252B (it) | 1989-02-22 | 1992-01-28 | Rotta Research Lab | Derivati della n fenil benzamide ad attivita' antiulcera ed antiallerica e procedimento per la loro preparazione |
| EP0428939B1 (de) * | 1989-11-21 | 1996-01-17 | Bayer Ag | Cumarinderivate, Verfahren zu ihrer Herstellung, ihre Verwendung und Thiazolyl-essigsäurederivate als Zwischenprodukte |
| EP0469477B1 (en) * | 1990-08-02 | 1995-09-20 | F. Hoffmann-La Roche Ag | Antiallergic combination |
| IE71647B1 (en) * | 1991-01-28 | 1997-02-26 | Rhone Poulenc Rorer Ltd | Benzamide derivatives |
| FR2674856B1 (fr) * | 1991-04-05 | 1993-07-30 | Esteve Labor Dr | Nouveaux antihistaminiques non sedatifs, derives de benzimidazole, leur procede de preparation et leur utilisation en tant que medicaments. |
| ES2102036T3 (es) | 1992-06-15 | 1997-07-16 | Celltech Therapeutics Ltd | Derivados con grupo fenilo trisustituido utilizados como inhibidores selectivos de la fosfodiesterasa iv. |
| US5521813A (en) * | 1993-01-15 | 1996-05-28 | Strategic Weather Services | System and method for the advanced prediction of weather impact on managerial planning applications |
| US5496826A (en) * | 1994-09-02 | 1996-03-05 | Bristol-Myers Squibb Company | Pharmaceutical methods of using heterocyclic derivatives of N-phenylamides |
| JP3223090B2 (ja) * | 1994-12-27 | 2001-10-29 | 三井化学株式会社 | フェニルベンズイミダゾール誘導体 |
| US5821258A (en) * | 1994-12-27 | 1998-10-13 | Mitsui Chemicals, Inc. | Phenylbenzimidazole derivatives |
| RU2084451C1 (ru) * | 1995-10-17 | 1997-07-20 | Акционерное общество закрытого типа "Алмазный Центр" | Способ получения 2-фенилбензимидазола |
| WO1998017267A1 (en) * | 1996-10-23 | 1998-04-30 | Zymogenetics, Inc. | Compositions and methods for treating bone deficit conditions |
| US6988076B2 (en) * | 1997-05-21 | 2006-01-17 | Khimetrics, Inc. | Strategic planning and optimization system |
| BR9910642A (pt) * | 1998-05-22 | 2001-10-09 | Avanir Pharmaceuticals | Análogos de benzimidazol como reguladores descendentes de ige |
| US6910017B1 (en) * | 1999-03-05 | 2005-06-21 | Profitlogic, Inc. | Inventory and price decision support |
| US6405175B1 (en) * | 1999-07-27 | 2002-06-11 | David Way Ng | Shopping scouts web site for rewarding customer referrals on product and price information with rewards scaled by the number of shoppers using the information |
| US6546387B1 (en) * | 1999-11-15 | 2003-04-08 | Transcom Software Inc. | Computer network information management system and method using intelligent software agents |
| US20020042739A1 (en) * | 2000-03-13 | 2002-04-11 | Kannan Srinivasan | Method and system for creating and administering internet marketing promotions |
| US20020023001A1 (en) * | 2000-07-11 | 2002-02-21 | Mcfarlin James A. | Method and apparatus for online creation and sale of custom local store marketing materials |
| WO2002041219A1 (en) * | 2000-11-15 | 2002-05-23 | Manugistics Atlanta, Inc. | Promotion pricing system and method |
| US20020198794A1 (en) * | 2001-06-21 | 2002-12-26 | Williams Edward P. | Inventory management system for determining suggested part stocking levels for a vehicle dealer |
-
1999
- 1999-05-21 BR BR9910642-6A patent/BR9910642A/pt not_active Application Discontinuation
- 1999-05-21 KR KR1020007013141A patent/KR100591652B1/ko not_active Expired - Fee Related
- 1999-05-21 EP EP99953286A patent/EP1079830A1/en not_active Withdrawn
- 1999-05-21 MX MXPA00011422A patent/MXPA00011422A/es not_active IP Right Cessation
- 1999-05-21 WO PCT/US1999/011490 patent/WO1999061020A1/en not_active Ceased
- 1999-05-21 IL IL13982899A patent/IL139828A0/xx unknown
- 1999-05-21 EP EP99925756A patent/EP1077695A2/en not_active Withdrawn
- 1999-05-21 NZ NZ508416A patent/NZ508416A/en unknown
- 1999-05-21 RU RU2000129524/15A patent/RU2236221C2/ru not_active IP Right Cessation
- 1999-05-21 CN CN99809102A patent/CN1311675A/zh active Pending
- 1999-05-21 CA CA002332985A patent/CA2332985A1/en not_active Abandoned
- 1999-05-21 WO PCT/US1999/011363 patent/WO1999061013A2/en not_active Ceased
- 1999-05-21 HU HU0102128A patent/HUP0102128A3/hu unknown
- 1999-05-21 BR BR9910641-8A patent/BR9910641A/pt not_active Application Discontinuation
- 1999-05-21 UA UA2000116724A patent/UA67775C2/uk unknown
- 1999-05-21 IL IL13982799A patent/IL139827A0/xx unknown
- 1999-05-21 CA CA002332989A patent/CA2332989A1/en not_active Abandoned
- 1999-05-21 CA CA002332999A patent/CA2332999A1/en not_active Abandoned
- 1999-05-21 PL PL99345560A patent/PL345560A1/xx not_active IP Right Cessation
- 1999-05-21 AU AU40942/99A patent/AU754562B2/en not_active Ceased
- 1999-05-21 ES ES99924442T patent/ES2241285T3/es not_active Expired - Lifetime
- 1999-05-21 DE DE69924607T patent/DE69924607T2/de not_active Expired - Fee Related
- 1999-05-21 CN CNA2005100859764A patent/CN1721411A/zh active Pending
- 1999-05-21 HU HU0102550A patent/HUP0102550A3/hu unknown
- 1999-05-21 CN CN99809101A patent/CN1317965A/zh active Pending
- 1999-05-21 MX MXPA00011470A patent/MXPA00011470A/es unknown
- 1999-05-21 UA UA2000116723A patent/UA67774C2/uk unknown
- 1999-05-21 WO PCT/US1999/011322 patent/WO1999061019A1/en not_active Ceased
- 1999-05-21 CN CNB998091057A patent/CN1219510C/zh not_active Expired - Fee Related
- 1999-05-21 PL PL99345952A patent/PL345952A1/xx unknown
- 1999-05-21 JP JP2000550480A patent/JP2002516277A/ja active Pending
- 1999-05-21 CZ CZ20004351A patent/CZ20004351A3/cs unknown
- 1999-05-21 EP EP99924442A patent/EP1077700B1/en not_active Expired - Lifetime
- 1999-05-21 NZ NZ508413A patent/NZ508413A/en unknown
- 1999-05-21 AU AU43120/99A patent/AU754943B2/en not_active Ceased
- 1999-05-21 JP JP2000550479A patent/JP2002516276A/ja active Pending
- 1999-05-21 US US09/316,870 patent/US6271390B1/en not_active Expired - Fee Related
- 1999-05-21 BR BR9910640-0A patent/BR9910640A/pt not_active IP Right Cessation
- 1999-05-21 MX MXPA00011467A patent/MXPA00011467A/es unknown
- 1999-05-21 RU RU2000129523/15A patent/RU2236220C2/ru not_active IP Right Cessation
- 1999-05-21 HU HU0101894A patent/HUP0101894A3/hu unknown
- 1999-05-21 IL IL13982699A patent/IL139826A0/xx unknown
- 1999-05-21 CZ CZ20004350A patent/CZ20004350A3/cs unknown
- 1999-05-21 AU AU41978/99A patent/AU4197899A/en not_active Abandoned
- 1999-05-21 PL PL99345219A patent/PL345219A1/xx unknown
- 1999-05-21 JP JP2000550473A patent/JP2002516274A/ja not_active Withdrawn
- 1999-05-21 AT AT99924442T patent/ATE292465T1/de not_active IP Right Cessation
-
2000
- 2000-02-21 ZA ZA200007754A patent/ZA200007754B/en unknown
- 2000-11-21 NO NO20005889A patent/NO20005889L/no unknown
- 2000-11-21 NO NO20005888A patent/NO20005888L/no unknown
- 2000-11-21 NO NO20005887A patent/NO20005887L/no not_active Application Discontinuation
- 2000-12-21 ZA ZA200007752A patent/ZA200007752B/en unknown
- 2000-12-21 ZA ZA200007753A patent/ZA200007753B/xx unknown
-
2001
- 2001-06-14 US US09/882,340 patent/US6451829B2/en not_active Expired - Fee Related
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE69924607T2 (de) | Benzimidazol-derivate als ige-modulatoren | |
| DE60221804T2 (de) | Benzimidazolderivate zur ige-modulierung und zellproliferationshemmung | |
| US6369091B1 (en) | Benzimidazole analogs as down-regulators of IgE | |
| US20030004203A1 (en) | Benzimidazole derivatives as modulators of IgE | |
| US20030100582A1 (en) | Benzimidazole compounds for regulating IgE | |
| US20040116466A1 (en) | Phenyl-aza-benzimidazole compounds for modulating IgE and inhibiting cellular proliferation | |
| DE69722220T2 (de) | 4-substituierte beta-carboline als immunomodulatoren | |
| KR20010031341A (ko) | ＩｇＥ에 작용하는 특성을 갖는 화합물 | |
| JP2010511616A (ja) | 水素化ピリド（４，３−ｂ）インドール（異性体）に基づいた認知機能および記憶を改善するための手段、当該手段に基づいた薬理学的手段、および当該手段の使用のための方法 | |
| KR20010032064A (ko) | ＩｇＥ의 조절제로서의 벤즈이미다졸 유도체 | |
| DE69427591T2 (de) | 7-(2-imidazolinylamino)quinolin-verbindungen als alpha-2 adrenorezeptor-agonisten | |
| US6303645B1 (en) | Benzimidazole derivatives as modulators of IgE | |
| US20020132808A1 (en) | Benzimidazole compounds for modulating IgE and inhibiting cellular proliferation | |
| DE69229125T2 (de) | Linderung oder vorbeugung des migräneanfalls mit mitteln zur hemmung der mastzellendegranulation | |
| DE102008003054A1 (de) | Verwendungen von 2-(Piperidinyl)methyl-2,3-dihydroimidazo(1,2-c)chinazolin-5(6H)-on zum Bereitstellen einer analgetischen Wirkung, antiallergischen Wirkung und Histamin-H1-Rezeptorantagonismuswirkung | |
| AU2003201363B2 (en) | Benzimidazole analogs as down-regulators of IgE | |
| EP1555020A2 (en) | Benzimidazole derivatives as modulators IgE | |
| HK1035326B (en) | Benzimidazole derivatives as modulators of ige | |
| HK1035326A1 (en) | Benzimidazole derivatives as modulators of ige |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 8364 | No opposition during term of opposition | ||
| 8339 | Ceased/non-payment of the annual fee |